Transgene : A strengthening of its cash position which should reassure
>Clear confidence in its historic shareholder - Last night, TNG published its annual results, which should reassure the markets following the signature of a new credit line with Institut Mérieux. Operating revenues were logically down at € 7.9m versus € 10.3m, mainly due to the termination of its agreement with AstraZeneca. On the other hand, operating expenses were well under control overall, despite the clinical advances made by the company. They came to € 37.9m, co...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.